New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareRetatrutide vs Gonadorelin

Retatrutide vs Gonadorelin

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Retatrutide
Sexual Health & LibidoAnti-Aging & Longevity
Gonadorelin
Summary
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
Half-Life
~10–12 days
~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
Admin Route
SubQ
SubQ, Intranasal
Research
Typical Dose
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
100 mcg
Frequency
Once weekly
Twice daily (every 12 hours)
Key Benefits
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
  • Maintains testicular size during TRT
  • Preserves fertility and sperm production during testosterone use
  • Stimulates endogenous LH/FSH production
  • Maintains HPG axis function during exogenous hormone use
  • Used for HCG-free TRT protocols
  • Helps restart natural testosterone production (PCT)
Side Effects
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
  • Injection site reactions
  • Headache
  • Nausea at initiation
  • Tachycardia (rare)
  • +1 more
Stacks With